Sun Pharmaceutical Industries reported strong financial results for the fourth quarter of FY26, supported by steady domestic demand, growth in emerging markets, and higher overall sales. The company posted a solid rise in quarterly profit and announced a final dividend of ₹5 per equity share for shareholders.
The earnings performance reflects continued strength in the company’s India formulations business, even as margins saw some pressure during the quarter.
Q4 FY26 Profit Rises Strongly Year-on-Year
For the quarter ended March 31, 2026, Sun Pharmaceutical Industries reported consolidated net profit of ₹2,714.03 crore, marking a 26.24% increase compared to ₹2,149.88 crore in the same quarter of the previous financial year.
However, on a sequential basis, profit declined 19.44% from ₹3,368.81 crore reported in the December 2025 quarter, indicating some moderation in quarterly earnings momentum.
Revenue Growth Driven by Domestic Business
Revenue from operations during Q4 FY26 stood at ₹14,611.79 crore, registering a 12.8% year-on-year increase from ₹12,958.84 crore in Q4 FY25.
Compared to the previous quarter, revenue declined 5.9% from ₹15,520.54 crore. Total sales during the quarter rose 13.6% year-on-year to ₹14,559.8 crore.
The company’s India formulations segment remained a key growth driver, benefiting from strong performance across multiple therapeutic categories.
EBITDA Improves but Margin Contracts
The company reported EBITDA of ₹3,955 crore for the March quarter, reflecting a 6.4% increase year-on-year.
Despite higher EBITDA, operating margins declined during the quarter. EBITDA margin stood at 27.1%, compared to 28.7% in the corresponding quarter last year.
The moderation in margins suggests higher operating costs or changing product mix during the period.
Full-Year FY26 Performance Remains Strong
For the entire financial year FY26, Sun Pharmaceutical Industries reported:
Net profit of ₹11,479.4 crore, up 5% year-on-year
Annual sales of ₹58,220.1 crore, rising 11.9% YoY
EBITDA of ₹17,731.4 crore, up 16.1% YoY
Importantly, annual EBITDA margin improved to 30.3% from 29% in FY25, indicating stronger operational efficiency over the full financial year.
Dividend Announcement for Shareholders
The board recommended a final dividend of ₹5 per equity share with a face value of ₹1 each for FY26.
This comes in addition to the interim dividend of ₹11 per share already paid earlier during the financial year. As a result, the total dividend payout for FY26 stands at ₹16 per share, unchanged from the previous year.
The consistent dividend payout reflects the company’s stable cash generation and shareholder return strategy.
India Business Continues to Lead Growth
The India formulations business reported strong growth of 14.8% during the quarter. According to the company, therapeutic segments such as:
Cardiovascular
Central Nervous System (CNS)
Gastroenterology
Orthopaedics
performed well and supported domestic revenue expansion.
India formulations contributed 33% of total consolidated sales during FY26, making it the company’s largest business segment.
Meanwhile, the US formulations business reported revenue of $459 million during the quarter, showing a slight decline compared to the previous year.
The emerging markets business delivered healthy growth, rising 13.6% to $1.27 billion during FY26.
Share Price Movement
Following the earnings announcement, Sun Pharmaceutical Industries shares closed at ₹1,840 on Thursday, down 2.71% for the session.
The stock touched an intraday high of ₹1,903 and a low of ₹1,833.10. The company’s market capitalisation stood at approximately ₹4.43 lakh crore.
Conclusion
Sun Pharmaceutical Industries delivered strong Q4 FY26 profit growth supported by higher revenue and solid domestic demand. While quarterly margins softened slightly, the company maintained healthy annual growth across sales and EBITDA.
The continued strength in India formulations, stable dividend payout, and growth in emerging markets reinforced the company’s operational resilience and long-term business stability during FY26.
Disclaimer:
This article is intended solely for educational and informational purposes. The securities or companies mentioned are provided as examples and should not be considered as recommendations. Nothing contained herein constitutes personal financial advice or investment recommendations. Readers are advised to conduct their own research and consult a qualified financial advisor before making any investment decisions.
Investments in securities markets are subject to market risks. Please read all related documents carefully before investing.
